CENTER VALLEY, PA--(Marketwired - September 18, 2013) - Aesculap Implant Systems, LLC., a leader in orthopaedic implant and instrument technology, is pleased to announce its sponsorship of a clinical study focused on furthering the science of navigated Total Knee Arthroscopy (TKA) as a proven method for improved alignment accuracy and reproducibility of the surgical technique. Aesculap Implant Systems' OrthoPilot® Navigation System and the Columbus® Knee System were featured in the study that showed a 100% survivorship at 5 years post-op when compared with other non-navigated TKA.
The Columbus Navigated TKA Clinical Study states that the major factors for a favorable long-term clinical and functional outcome after conventional TKA are based on correct implant positioning and restoration of the mechanical axis and soft tissue balancing to reduce aseptic loosening. The use of computer-assisted tools for TKA allows more accurate and reproducible positioning and alignment of TKA components compared with conventional techniques.
Published in the Orthopedics journal in March 2013, the objective of the study was to analyze data from a minimum 5 year follow-up of navigated TKA to determine the intra-operative alignment and stability measurements, the functional outcomes and survival rates of high-flexion, high-conformity unresurfaced patella TKA and the range of motion (ROM) of the high-flexion TKA system during the study period.
The Columbus Navigated TKA study is a retrospective analysis of 100 consecutive patients who received primary patella-sparing TKA. At 5-years post-op, mid-term TKA survival rate, clinical and radiological outcomes, and visual analog scale (VAS) pain and satisfaction scores were analyzed. Some key study findings were:
The key finding of the study showed a 100% survivorship at 5-years post-op when compared with other non-navigated TKA. The study also revealed an improved ROM from 95º preoperatively to 110º postoperatively.
Aesculap continuously strives to improve the quality of patients lives through the delivery of innovative operative solutions. "The positive results of this study not only support our mission to improve the quality of a patient's life, but represent a new benchmark in total knee arthroplasty surgery," stated Chuck DiNardo, President of Aesculap.
The Columbus Navigated TKA System: Clinical and Radiological Results at a Minimum of 5 Years with Survivorship Analysis study is available in the March 2013 issue of Orthopedics. The article may be viewed or downloaded from www.healio.com or use the following link: http://www.healio.com/orthopedics/journals/ORTHO/%7B65317356-34C4-46E2-9B89-C8B7B3739F24%7D/Columbus-Navigated-TKA-System-Clinical-and-Radiological-Results-at-a-Minimum-of-5-Years-With-Survivorship-Analysis
For additional information on the study or Aesculap's orthopaedic product offering, please visit www.aesculapimplantsystems.com/ortho
About Aesculap Implant Systems, LLC
Aesculap Inc., a B. Braun company, founded in 1867 in Tuttlingen, Germany, is the world's largest and one of the most respected manufacturers of surgical instruments and sterilization container. Aesculap is a leading privately-owned manufacturing company, passionately committed to providing high-quality, innovative products and services to all surgical disciplines, with particular focus in the fields of General, Neuro, Spine and Orthopaedics.
Aesculap Implant Systems, LLC, established by Aesculap, Inc. in 2005, focuses on delivering innovative solutions to the spine and orthopaedic markets. Aesculap Implant Systems maintains a surgeon/patient focus with the goal of improved operative procedures and patient outcomes leading to an improved quality of life. For more information about Aesculap Implant Systems or its medical products, call 800-234-9179, email us at email@example.com or visit www.AesculapImplantSystems.com.
About B. Braun
B. Braun Medical Inc. (B.Braun), a leader in infusion therapy and pain management, develops, manufactures, and markets innovative medical products and services to the healthcare industry. The Company is committed to eliminating preventable treatment errors and enhancing patient, clinician and environmental safety. Guided by its "Sharing Expertise®" philosophy, B.Braun continuously exchanges knowledge with customers, partners and clinicians to address the critical issues of improving care and lowering costs.
The B.Braun group of companies includes B.Braun, Aesculap® and CAPS®. B.Braun's U.S. headquarters is located in Bethlehem, Pennsylvania, with its global headquarters based in Melsungen, Germany. It employs more than 44,000 employees in more than 50 countries throughout the world. To learn more about B.Braun visit www.bbraunusa.com.
The following files are available for download: